Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhangzhou Pien Tze Huang Pharmaceutical Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, BRIAN E MCDOWELL, who is the busiest examiner for the portfolio with 1 pending case. The prosecution activity is concentrated in 1 distinct art unit. This distribution suggests a specific technological scope for the current pending portfolio.
Practitioners can anticipate a direct interaction given that all pending work resides with the 1 examiner named. Because BRIAN E MCDOWELL is the examiner involved, his previous examination history and preferences will be factors in determining the prosecution timeline. The presence of the 1 distinct art unit defines the procedural landscape, as there are no requirements from different units. This 1 pending office action represents the current active engagement with the USPTO in this sector. The Biotechnology & Pharmaceuticals technology area encompasses the entirety of this pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| No statute on record | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDOWELL, BRIAN E | 1 | 74.0% | +31.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695174 | 2,6-PIPERIDINEDIONE COMPOUND AND APPLICATION THEREOF | MCDOWELL, BRIAN E | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18695174 | 2,6-PIPERIDINEDIONE COMPOUND AND APPLICATION THEREOF | MCDOWELL, BRIAN E | 1624 | Other | Non-Final OA | — | Pending | Mar 25, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhangzhou Pien Tze Huang Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brian E Mcdowell has the most, with 1 of Zhangzhou Pien Tze Huang Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
